By Fineline Cube 
hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In its first year of commercialization, the company achieved revenues of RMB 202 million (USD 27.7 million) and maintained a cash reserve of RMB 1.89 billion (USD 260 million). Its flagship products, Ouyoubi (a neratinib biosimilar) and Dipaite (a pazopanib biosimilar), demonstrated impressive market uptake, covering 1,000 and 500 target hospitals respectively. Ouyoubi secured a 27% market share, while Dipaite achieved a 12% share of their respective originators.
Product Pipeline and Innovation
Asieris Pharma’s pipeline currently comprises 12 products and 16 investigational programs. APL-1702, a drug-device combination for photodynamic non-surgical treatment of cervical high-grade squamous intraepithelial lesions (HSIL), is under regulatory review in China. Hexvix (APL-1706), a diagnostic imaging agent for photodynamic blue light cystoscopy in bladder cancer detection, received NMPA approval in November 2024. Market launches for these innovative products are imminent.-Fineline Info & Tech